P.D. Hinduja Hospital & Medical Research Centre is focusing its efforts to create awareness around the increasing trend and effective management of Antimicrobial Resistance (AMR).
AMR infections usually require the use of second line and third line treatments which can cause serious side-effects, such as organ failure and prolonged care and recovery, which could go on for months. The overall misuse and overuse of consumption of antibiotics which should only be used to treat the most serious infections like difficult-to-treat bacterial infections, and poor infection prevention and control, increase the spread of AMR. This rise in mortality and morbidity due to AMR infections is very alarming and the WHO and CDC have suggested that steps can and should be taken at all levels of society to reduce the impact and control the spread of resistance. Individuals, policy makers (government), healthcare professionals and the healthcare industry should all collectively contribute towards reducing the incidence of AMR infections.
Joy Chakraborty, Chief Operating Officer, P.D Hinduja Hospital & MRC said, “Stakeholders across India are working together to combat the alarming rate of antimicrobial resistance (AMR). While all precautions are taken, this challenge frequently extends beyond basic hospital hygiene and is rapidly becoming a global health concern. Adopting antimicrobial stewardship is a critical component of this, and one of the first steps that must be taken is to raise awareness and understanding of AMR through effective communication. At P.D Hinduja Hospital, we believe in bringing about a change in society and reaching greater heights in the service of humanity; and be at the forefront of bringing global quality medical solutions for the benefit of our patients. P.D. Hinduja Hospital & MRC is one of ICMR’s state center for antimicrobial stewardship and serves as a mentor for other institutes in the city.” commented.”
While there is no standardised region wise data on resistance rates, a few reports from hospitals and communities suggest that the overall resistance level is increasing by 5 to 10 per cent every year for broad-spectrum antimicrobials which are highly misused. A data analysis done by Indian Council for Medical Research (ICMR) between January 1 and December 31, 2021, found a sustained increase in drug-resistant pathogens, resulting in difficulty to treat certain infections with available medicines. This is a major concern because a resistant infection can spread to others and potentially impose huge costs to individuals and society.
Shyamakant Giri, Managing Director & President, India Business and Emerging Markets, Amneal Healthcare said “As industry patrons, it is also our responsibility to develop or collaborate in developing platforms which help in preventing transmission of hospital infections and antimicrobial drug resistance. Uniport is a first-of-its-kind closed IV technology platform that is being manufactured by Amneal for India, in India. This will set new standards for delivery of IV solutions in the country. The INICC (International Nosocomial Infection Control Consortium), recommends use of closed infusion systems for administration of clinical treatments in hospitals. The government of India has taken several measures to control the rise of AMR in India, we look forward to partnering with stakeholders like P.D. Hinduja Hospital & MRC to reduce this burden by increasing access to this innovative technology for advanced care.”
Amneal Healthcare, subsidiary of NYSE-listed Amneal Pharmaceuticals, announced its commercial operations in India recently. Uniport is a IV with multipurpose single port bag offering a closed-infusion system. The Uniport bag introduces several technological advancements for optimum utilisation like self-collapsibility, easy to squeeze, transparency for clear visibility.
Discussion about this post